Cefutus Clav 250/125mg Tablet 6s

Cefutus Clav 250/125mg Tablet 6s is a broad-spectrum antibacterial combination consisting of Cefuroxime, a second-generation cephalosporin, and Clavulanic Acid, a beta-lactamase inhibitor. This formulation is designed to extend the antibacterial activity of Cefuroxime against beta-lactamase-producing organisms.

Cefuroxime binds to penicillin-binding proteins (PBPs) within the bacterial cell wall. These proteins are essential for cross-linking peptidoglycan chains, which provide structural integrity to the bacterial cell wall. By inhibiting these PBPs, Cefuroxime disrupts cell wall synthesis, resulting in cell lysis and bacterial death. It is active against a wide range of gram-positive and gram-negative bacteria, including Streptococcus pneumoniae, Haemophilus influenzae, Escherichia coli, Klebsiella species, and Proteus mirabilis.

However, many bacteria produce beta-lactamases that can inactivate cephalosporins by cleaving the beta-lactam ring. Clavulanic Acid is structurally similar to beta-lactam antibiotics but has minimal intrinsic antibacterial activity. Its primary role is to bind irreversibly to beta-lactamase enzymes, thereby protecting Cefuroxime from degradation. This allows Cefuroxime to maintain its antibacterial activity even against beta-lactamase-producing strains.

Both components are well absorbed after oral administration. Cefuroxime axetil (oral prodrug) is hydrolysed in the intestinal mucosa and bloodstream to active Cefuroxime. Peak plasma concentrations are typically reached within 2–3 hours. The drug is widely distributed throughout the body, including the lungs, sinuses, middle ear fluid, skin, and the urinary tract. Cefuroxime is primarily eliminated unchanged by the kidneys, while Clavulanic Acid undergoes hepatic metabolism and renal excretion.

This combination is widely used in outpatient and inpatient settings for moderate-to-severe infections in which beta-lactamase-producing pathogens are suspected or confirmed. Completing the prescribed course is essential to ensure full eradication of bacteria and to prevent relapse or resistance.

Respiratory Tract Infections

Cefutus Clav 250/125mg Tablet 6s is commonly prescribed for infections of the upper and lower respiratory tract, including acute bacterial sinusitis, pharyngitis, tonsillitis, bronchitis, and community-acquired pneumonia. It is particularly useful when the infection is caused by resistant strains of Haemophilus influenzae or Streptococcus pneumoniae.

Ear, Nose, and Throat Infections

This combination is effective in treating otitis media, sinus infections, and throat infections where beta-lactamase-producing bacteria are suspected.

Urinary Tract Infections (UTIs)

Cefutus Clav 250/125mg Tablet 6s is used in uncomplicated and complicated urinary tract infections, including cystitis and pyelonephritis, caused by susceptible gram-negative organisms.

Skin and Soft Tissue Infections

It is effective against bacterial skin infections such as cellulitis, impetigo, infected wounds, and abscesses caused by susceptible organisms, including Staphylococcus aureus.

Bone and Joint Infections

In certain cases, Cefutus Clav 250/125mg Tablet 6s may be prescribed as part of therapy for osteomyelitis or septic arthritis caused by susceptible bacteria.

Dental Infections

Dentists may prescribe this combination for severe dental abscesses, periodontal infections, and post-surgical oral infections where anaerobic and resistant organisms may be present.

• Enhanced Antibiotic Protection

Clavulanic Acid protects Cefuroxime from destruction by beta-lactamase enzymes, ensuring the antibiotic remains effective against resistant bacteria.

• Broad-Spectrum Coverage

The combination provides activity against both gram-positive and gram-negative bacteria, allowing treatment of mixed or uncertain infections.

• Reduced Risk of Treatment Failure

By overcoming bacterial resistance mechanisms, Cefutus Clav 250/125mg Tablet 6s lowers the chance of infection persistence and relapse.

• Suitable for Multiple Infection Sites

Due to its good tissue penetration, the medicine can effectively treat infections in the lungs, urinary tract, skin, and sinuses.

• Convenient Oral Therapy

Oral administration allows patients to receive potent antibiotic therapy without hospitalisation, improving compliance and comfort.

More Common Side Effects

• Nausea

• Vomiting

• Diarrhea

• Abdominal discomfort

• Headache

Less Common Side Effects

• Skin rash

• Mild itching

• Dizziness

• Temporary elevation in liver enzymes

• Altered taste sensation

Serious Side Effects (Seek Medical Help Immediately)

• Severe allergic reactions, including anaphylaxis

• Severe skin reactions such as Stevens-Johnson syndrome

• Persistent or bloody diarrhoea indicates Clostridioides difficile infection

• Severe abdominal pain or liver dysfunction symptoms, such as jaundice

• Seizures (rare, usually in patients with kidney impairment)

Cefutus Clav 250/125mg Tablet 6s should be taken exactly as prescribed by a qualified healthcare professional. It is usually recommended to take the tablet after meals to enhance absorption and reduce gastrointestinal irritation.

Swallow the tablet whole with a glass of water. Do not crush or chew unless your doctor advises you to. Take doses at evenly spaced intervals to maintain consistent antibiotic levels in the bloodstream. Skipping doses or stopping the medicine early may lead to treatment failure and antibiotic resistance.

Cefuroxime acts by inhibiting bacterial cell wall synthesis. It binds to specific penicillin-binding proteins within the bacterial cell wall and prevents the formation of cross-links in the peptidoglycan. Without these cross-links, the bacterial cell wall becomes weak and unable to withstand osmotic pressure, leading to cell rupture and death.

Clavulanic Acid functions as a suicide inhibitor of beta-lactamase enzymes. Many resistant bacteria produce these enzymes to inactivate beta-lactam antibiotics. Clavulanic Acid binds irreversibly to the active site of beta-lactamase, preventing it from destroying Cefuroxime. As a result, Cefuroxime can continue to exert its antibacterial action.

This synergistic mechanism ensures effective treatment of infections caused by both susceptible and beta-lactamase-producing bacteria.

• Complete the full course of antibiotics

• Take doses at regular intervals

• Avoid self-medication or sharing antibiotics

• Report severe diarrhea or allergic symptoms immediately

• Maintain hydration during treatment

• Avoid unnecessary antibiotic use to reduce resistance development

• Alcohol (Moderate)

Alcohol does not directly inactivate Cefuroxime or Clavulanic Acid, but it may increase the risk of gastrointestinal upset, dizziness, and dehydration. It may also weaken the immune system’s ability to fight infection effectively. Patients are advised to limit or avoid alcohol during antibiotic therapy to ensure optimal recovery.

• High-Fat Meals (Mild)

Taking Cefutus Clav 250/125mg Tablet 6s with food improves Cefuroxime absorption, especially with fatty meals, which enhance bioavailability. However, excessively heavy meals may slightly delay the onset of action. Balanced meals are recommended.

• Probiotic Foods (Beneficial)

Fermented foods such as yoghurt, kefir, and buttermilk may help restore gut microbiota disturbed by antibiotic therapy and reduce the risk of antibiotic-associated diarrhoea.

• Anticoagulants such as warfarin

• Probenecid

• Diuretics

• Other nephrotoxic drugs

• Oral contraceptives

• Penicillin Allergy (Severe)

Patients with a history of severe hypersensitivity to penicillins or other cephalosporins may experience cross-reactivity. Anaphylaxis risk should be carefully evaluated before prescribing.

• Kidney Disease (High)

Reduced renal clearance can lead to accumulation of Cefuroxime, increasing the risk of neurotoxicity and seizures. Dose adjustment is required.

• Liver Disease (Moderate)

Clavulanic Acid has been associated with rare cases of cholestatic hepatitis. Monitoring of liver enzymes is recommended during prolonged use.

• Gastrointestinal Disorders (Moderate)

Patients with a history of colitis or inflammatory bowel disease may be at increased risk of antibiotic-associated diarrhea or Clostridioides difficile infection.

If you miss a dose, take it as soon as you remember. However, if the next scheduled dose is near, skip the missed dose and continue with your regular dosing schedule. Do not double the dose to compensate for a missed one, as this may increase the risk of side effects without improving treatment effectiveness.